JUL 09, 2019 10:33 AM PDT

Effective Treatment for Ulveal Melanoma

WRITTEN BY: Nouran Amin

Ulveal melanoma is a rare and aggressive type of melanoma that targets the eye and affects an estimated 2,500 people in the United States annually. Nearly half of these diagnoses will go on to develop metastatic uveal melanoma that will target other parts of the body—mainly the liver. Prognosis is often poor with a median survival of 17 to 20 months. However, researchers have now identified a drug combination designed to target the metastatic uveal melanoma cells in preclinical studies

Learn more about uveal melanoma:

Researchers have designed uveal melanoma cell lines that were resistant to MEK inhibitors—drugs that target the MEK protein implicated in MAPK signaling of melanoma patients—and performed proteomic analysis to examine what signaling pathways were activated during the MEK inhibitor resistance process.

“We identified a number of putative escape pathways that were upregulated following MEK inhibition, including the PI3K/AKT pathway, ROR1/2 and IGF-1R signaling,” explained Keiran Smalley, PhD, director of Moffitt’s Donald A. Adam Melanoma and Skin Cancer Center of Excellence.

Researchers were hopeful that through the identification of critical signaling pathways, they can understand how uveal melanoma cells become resistant to treatment and then counteract with an additional drug alongside MEK inhibitors.

Findings were published in Clinical Cancer Research and reveal that histone deacetylase (HDAC) inhibitors drugs, particularly panobinostat, were most effective in targeting two critical pathways in the resistance process: AKT and YAP signaling.

“Our finding that a clinically approved pan-HDAC inhibitor was effective at simultaneously limiting YAP and AKT signaling in uveal melanoma cells suggests this could be a good candidate for future clinical development,” explained Smalley.

In mouse studies, these results indicate a successful combination treatment with HDAC panobinostat along with and the MEK inhibitor trametinib is effective at uveal melanoma tumor growth reduction.

Source: Moffitt Cancer Center

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JAN 15, 2020
Drug Discovery & Development
JAN 15, 2020
A New Drug Target for Substance Abuse
Research carried out by the University of Minnesota Medical School indicates a new drug target for treating a drug addiction. Researchers note that the dru...
FEB 04, 2020
Cancer
FEB 04, 2020
The role of SRR in colorectal cancer
Researchers from Osaka University have recently discovered a new function of the multifunctional enzyme entitled serine racemase (SRR). According to the te...
FEB 26, 2020
Microbiology
FEB 26, 2020
NIAID Tests Remdesivir as a Treatment for COVID-19
A case of coronavirus has now occured in the US in someone without a known link to an infected person or travel....
MAR 05, 2020
Drug Discovery & Development
MAR 05, 2020
Molecule Found in Oranges Could Treat Obesity
Scientists at Western University isolated a molecule from oranges and sweet tangerines called ‘nobiletin’. Through the studies on mice the mole...
MAR 18, 2020
Genetics & Genomics
MAR 18, 2020
Finding a Treatment for Fetal Alcohol Spectrum Disorder
When developing fetuses are exposed to any amount of alcohol, they are at risk for a variety of irreversible birth defects....
MAR 08, 2020
Drug Discovery & Development
MAR 08, 2020
DNA Origami Helps With Cancer Therapeutics
A study published in the Proceedings of the National Academy of Sciences, describes how researchers designed molecules known as "peptoid-coated DNA or...
Loading Comments...